Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cholera
Conditions
Cholera
Trial Timeline
Mar 1, 2014 → Aug 1, 2015
NCT ID
NCT01949675About Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell is a approved stage product being developed by Sanofi for Cholera. The current trial status is completed. This product is registered under clinical trial identifier NCT01949675. Target conditions include Cholera.
What happened to similar drugs?
1 of 7 similar drugs in Cholera were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02434822 | Phase 3 | Completed |
| NCT01949675 | Approved | Completed |
Competing Products
9 competing products in Cholera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azithromycin | Pfizer | Phase 3 | 40 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Phase 3 | 40 |
| Ciprofloxacin | Bayer | Phase 3 | 37 |
| PXVX0200 + placebo | Bavarian Nordic | Phase 3 | 37 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 3 | 37 |
| VAXCHORA (Cholera Vaccine, Live, Oral) | Bavarian Nordic | Approved | 40 |
| PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo | Bavarian Nordic | Phase 3 | 37 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 1 | 26 |
| PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol | Emergent BioSolutions | Phase 2 | 25 |